| http://purl.uniprot.org/citations/17594693 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/17594693 | http://www.w3.org/2000/01/rdf-schema#comment | "Given the poor survival rate and efficacy of current therapy for esophageal adenocarcinoma (EAC), there is a need to identify and develop new therapeutic targets for treatment. Microarray analysis (Affymetrix U133A GeneChips, Robust Multi-Chip Analysis) was used to expression profile 11 normal squamous and 18 Barrett's esophagus biopsies, 7 surgically resected EACs and 3 EAC cell lines. Two hundred transcripts representing potential therapeutic targets were identified using the following criteria: significant overexpression in EAC by analysis of variance (p = 0.05, Benjamini Hochberg false discovery rate); 3-fold increase in EAC relative to normal and Barrett's esophagus and expression in at least 2 of the 3 EAC cell lines. From the list of potential targets we selected TNFRSF12A/Fn14/TWEAK receptor, a tumor necrosis factor super-family receptor, for further validation based on its reported role in tumor cell survival and potential as a target for therapy. Fn14 protein expression was confirmed in SEG-1 and BIC-1 cell lines, but Fn14 was not found to affect tumor cell survival after exposure to chemotherapeutics as expected. Instead, a novel role in EAC was discovered in transwell assays, in which modulating Fn14 expression affected tumor cell invasion. Fn14's potential as a therapeutic target was further supported by immunohistochemistry on a tissue microarray of patient samples that showed that Fn14 protein expression increased with disease progression in EAC."xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.org/dc/terms/identifier | "doi:10.1002/ijc.22898"xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/author | "Nelson M.A."xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/author | "Tran N.L."xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/author | "Berens M.E."xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/author | "Montgomery E.A."xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/author | "Bhattacharyya A.K."xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/author | "Watts G.S."xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/author | "Sampliner R.E."xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/date | "2007"xsd:gYear |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/name | "Int J Cancer"xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/pages | "2132-2139"xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/title | "Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma."xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://purl.uniprot.org/core/volume | "121"xsd:string |
| http://purl.uniprot.org/citations/17594693 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/17594693 |
| http://purl.uniprot.org/citations/17594693 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/17594693 |
| http://purl.uniprot.org/uniprot/#_Q9NP84-mappedCitation-17594693 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/17594693 |
| http://purl.uniprot.org/uniprot/Q9NP84 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/17594693 |